MARGENZA offers a chance for more time without cancer growing and spreading
Clinical trial results
In a clinical trial of 536 patients, people treated with MARGENZA plus chemotherapy lived longer without the cancer growing or spreading than people who were treated with trastuzumab plus chemotherapy.
MARGENZA plus chemotherapy lowered the chance of disease progression by 24% compared to trastuzumab plus chemotherapy
Median time without disease progression
MARGENZA plus chemotherapy
Trastuzumab plus chemotherapy
The median age of participants in the study was 56 years (age range 27–86 years), and 78% of patients were less than 65 years old.
Patients enrolled in the study had metastasis in the bone, lymph node, lung, liver, breast, skin, or brain.
A choice of chemotherapy
MARGENZA is FDA-approved to be used in combination with chemotherapy. That gives your doctor the freedom to consider various chemotherapy options based on your individual needs, past treatments, and experience.
In the clinical trial where MARGENZA was studied, MARGENZA was used with a choice of 4 chemotherapies, which included capecitabine, eribulin, gemcitabine, and vinorelbine.
Here's how you'll get MARGENZA
MARGENZA is given as an infusion. You’ll receive this treatment at an infusion center.
Treatment is given on a 21-day cycle (every 3 weeks)
Your first MARGENZA infusion is given over 2 hours, with additional doses taking less time (approximately 30 minutes)
On days when both MARGENZA and chemotherapy are to be administered, MARGENZA may be administered immediately
after chemotherapy completion.
Important Safety Information
What is the most important information I should know about MARGENZA?
MARGENZA can cause serious side effects, including:
- Heart problems that may affect your heart’s ability to pump blood. Your doctor will run tests to monitor your heart function before and during treatment with MARGENZA. Based on test results, your doctor may hold or
discontinue treatment with MARGENZA.
- Tell your healthcare provider right away if you get any of the following signs and symptoms: new or worsening shortness of breath, coughing, feeling tired, swelling of the ankles or legs, swelling of the face, irregular heart beat or palpitations, sudden weight gain of more than 5 pounds in 24 hours, dizziness or feeling light-headed, or loss of consciousness.
- Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with MARGENZA. Exposure to MARGENZA during pregnancy or within 4 months prior
to conception can result in fetal harm.
- If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with MARGENZA.
- Birth control should be used while receiving MARGENZA and for 4 months after your last dose of MARGENZA.
What are other possible serious side effects of MARGENZA?
Infusion-related reactions. MARGENZA is a medicine that is delivered into a vein through a needle as an infusion. MARGENZA has been associated with infusion-related reactions which can include fever, chills, joint pain, cough, dizziness, tiredness, nausea, vomiting, headache, sweating, fast heart rate, low blood pressure, itching, rash, hives, and shortness of breath. Your healthcare team will monitor you during treatment with MARGENZA and may slow or stop your infusion if you have side effects. You may need to permanently stop MARGENZA if you have a severe infusion reaction.
Before you receive MARGENZA, tell your doctor if you are breastfeeding. It is not known if MARGENZA could pass into breast milk and harm your baby.
What are the most common side effects of MARGENZA in combination with chemotherapy?
The most common side effects with MARGENZA in combination with chemotherapy are fatigue/weakness, nausea, diarrhea, vomiting, constipation, headache, fever, hair loss, abdominal pain, peripheral neuropathy (weakness, numbness, pain, and/or tingling in hands and feet), joint and muscle pain, cough, decreased appetite, shortness of breath, infusion-related reactions, redness/swelling and pain on the palms of the hands and soles of the feet (hand-foot syndrome), and pain in arms and legs.
These are not all the possible side effects of MARGENZA. Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects.
What does MARGENZA treat?
MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Please see full Prescribing Information, including Boxed Warning.
This website contains clinical information intended for US healthcare professionals.
Are you sure you want to leave?
You are now leaving the MARGENZA® (margetuximab-cmkb) website.
You are about to go to a website that is operated by an independent third party. Your activities on the external website will be managed by its policies and practices. By clicking “Continue,” you will go to the external website.